相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis
Ashna Talwar et al.
EXPERIMENTAL NEUROLOGY (2023)
Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures
Doodipala Samba Reddy et al.
EXPERIMENTAL NEUROLOGY (2023)
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
Joyce Y. Wu et al.
EPILEPSIA (2022)
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial
Elizabeth A. Thiele et al.
EPILEPSIA (2022)
Contusion brain damage in mice for modelling of post-traumatic epilepsy with contralateral hippocampus sclerosis: Comprehensive and longitudinal characterization of spontaneous seizures, neuropathology, and neuropsychiatric comorbidities
Victoria M. Golub et al.
EXPERIMENTAL NEUROLOGY (2022)
Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions
Elaine C. Wirrell et al.
EPILEPSIA (2022)
A scoping review on cannabidiol therapy in tuberous sclerosis: Current evidence and perspectives for future development
Debopam Samanta
EPILEPSY & BEHAVIOR (2022)
Antiseizure Medications for Adults With Epilepsy A Review
Andres M. Kanner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Therapeutic Basis of Generic Substitution of Antiseizure Medications
Sarah Elmer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2022)
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials
Boudewijn Gunning et al.
ACTA NEUROLOGICA SCANDINAVICA (2021)
Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex A Placebo-Controlled Randomized Clinical Trial
Elizabeth A. Thiele et al.
JAMA NEUROLOGY (2021)
Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research
Valentina Franco et al.
NEUROPHARMACOLOGY (2021)
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study
Richard F. M. Chin et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2021)
Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis
Nir Treves et al.
SCIENTIFIC REPORTS (2021)
Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials
Michael Privitera et al.
EPILEPSIA (2021)
Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy
Tyler E. Gaston et al.
EPILEPSY & BEHAVIOR (2021)
Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis
Doodipala Samba Reddy et al.
NEUROSCIENCE LETTERS (2021)
Cannabidiol modifies the seizure expression and effects of antiseizure drugs in a rat model of recurrent severe seizures
Christian Lizette Frias-Soria et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2021)
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy
Lyndsey L. Anderson et al.
BRITISH JOURNAL OF PHARMACOLOGY (2021)
Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial
Ingrid E. Scheffer et al.
EPILEPSIA (2021)
Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial
Anup D. Patel et al.
EPILEPSIA (2021)
Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
Jennifer Madan Cohen et al.
EPILEPSIA (2021)
Developmental and epileptic encephalopathies: recognition and approaches to care
Sharika Raga et al.
EPILEPTIC DISORDERS (2021)
Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex
Daniel Ebrahimi-Fakhari et al.
PEDIATRIC NEUROLOGY (2020)
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome A Randomized Clinical Trial
Ian Miller et al.
JAMA NEUROLOGY (2020)
Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials
Meir Bialer et al.
EPILEPSIA (2020)
Mechanisms of action of currently used antiseizure drugs
Graeme J. Sills et al.
NEUROPHARMACOLOGY (2020)
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Edward Chesney et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials
Orrin Devinsky et al.
ACTA NEUROLOGICA SCANDINAVICA (2020)
Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies
Catherine A. Christian et al.
PHARMACOLOGICAL REVIEWS (2020)
Cannabidiol interactions with voltage-gated sodium channels
Lily Goodyer Sait et al.
ELIFE (2020)
Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent
Royston A. Gray et al.
CANNABIS AND CANNABINOID RESEARCH (2020)
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results
Linda C. Laux et al.
EPILEPSY RESEARCH (2019)
Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus
Abbie D. Leino et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2019)
Cannabinoid therapy in epilepsy
Santoshi Billakota et al.
CURRENT OPINION IN NEUROLOGY (2019)
Preclinical safety and efficacy of cannabidivarin for early life seizures
Megan N. Huizenga et al.
NEUROPHARMACOLOGY (2019)
Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy
Angela K. Birnbaum et al.
EPILEPSIA (2019)
Effects of cannabidiol on brivaracetam plasma levels
Kerstin A. Klotz et al.
EPILEPSIA (2019)
Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol
Jerzy P. Szaflarski et al.
EPILEPSY & BEHAVIOR (2019)
Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures
Mark Mascal et al.
SCIENTIFIC REPORTS (2019)
Cannabidiol Interacts Significantly with Everolimus-Report of a Patient with Tuberous Sclerosis Complex
Adelheid Wiemer-Kruel et al.
NEUROPEDIATRICS (2019)
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
Lyndsey L. Anderson et al.
EPILEPSIA (2019)
Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models
Pabitra Hriday Patra et al.
EPILEPSIA (2019)
Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
Orrin Devinsky et al.
EPILEPSIA (2019)
Cannabis-based products for pediatric epilepsy: A systematic review
Jesse Elliott et al.
EPILEPSIA (2019)
A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
Gilmour Morrison et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study
Rima Nabbout et al.
EPILEPSIA OPEN (2019)
Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus
Dipan C. Patel et al.
EPILEPSIA OPEN (2019)
A resurging boom in new drugs for epilepsy and brain disorders
Iyan Younus et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results
Jerzy P. Szaflarski et al.
EPILEPSIA (2018)
Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations
Paolo Curatolo et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2018)
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
Elizabeth A. Thiele et al.
LANCET (2018)
Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons
Alex Straiker et al.
MOLECULAR PHARMACOLOGY (2018)
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky et al.
NEUROLOGY (2018)
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs A 30-Year Longitudinal Cohort Study
Zhibin Chen et al.
JAMA NEUROLOGY (2018)
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study
Jerzy P. Szaflarski et al.
EPILEPSY & BEHAVIOR (2018)
Inhibitory effects of cannabidiol on voltage-dependent sodium currents
Mohammad-Reza Ghovanloo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age
Jose A. Crippa et al.
FRONTIERS IN IMMUNOLOGY (2018)
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Lesley Taylor et al.
CNS DRUGS (2018)
Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
Simona Lattanzi et al.
DRUGS (2018)
Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial
Kerri A. Schoedel et al.
EPILEPSY & BEHAVIOR (2018)
Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats
Megan N. Huizenga et al.
EPILEPSIA (2017)
Dravet syndrome and its mimics: Beyond SCN1A
Dora Steel et al.
EPILEPSIA (2017)
Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection
Evan C. Rosenberg et al.
EPILEPSY & BEHAVIOR (2017)
Cannabinoids in treatment-resistant epilepsy: A review
Brooke K. O'Connell et al.
EPILEPSY & BEHAVIOR (2017)
Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP)
Brian D. Klein et al.
NEUROCHEMICAL RESEARCH (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors
T. Bakas et al.
PHARMACOLOGICAL RESEARCH (2017)
Epigenetic interventions for epileptogenesis: A new frontier for curing epilepsy
Iyan Younus et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome
Joshua S. Kaplan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
From genotype to phenotype in Dravet disease
Svetlana Gataullina et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2017)
Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders
Alline C. Campos et al.
FRONTIERS IN PHARMACOLOGY (2017)
Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy
Raquel A. Do Val-da Silva et al.
FRONTIERS IN PHARMACOLOGY (2017)
Cannabidiol attenuates OGD/R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons
Shanshan Sun et al.
REDOX BIOLOGY (2017)
Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy
Bryan L. Clossen et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol
Reesha R. Patel et al.
BRAIN (2016)
Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex
Evan J. Hess et al.
EPILEPSIA (2016)
Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure
Mahshid Hosseinzadeh et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2016)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky et al.
LANCET NEUROLOGY (2016)
Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus
A. Vanessa Stempel et al.
NEURON (2016)
Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors
Raquel Linge et al.
NEUROPHARMACOLOGY (2016)
CBD-enriched medical cannabis for intractable pediatric epilepsy The current Israeli experience
Michal Tzadok et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2016)
The Pharmacological Basis of Cannabis Therapy for Epilepsy
Doodipala Samba Reddy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Dissecting the phenotypes of Dravet syndrome by gene deletion
Moran Rubinstein et al.
BRAIN (2015)
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R. B. Laprairie et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Alexandra L. Geffrey et al.
EPILEPSIA (2015)
Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption
Cristina A. J. Stern et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
Cannabinoids and Epilepsy
Evan C. Rosenberg et al.
NEUROTHERAPEUTICS (2015)
Cannabinoids in the Treatment of Epilepsy
Daniel Friedman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The case for medical marijuana in epilepsy
Edward Maa et al.
EPILEPSIA (2014)
Lennox-Gastaut syndrome: A consensus approach to differential diagnosis
Blaise F. D. Bourgeois et al.
EPILEPSIA (2014)
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
Orrin Devinsky et al.
EPILEPSIA (2014)
Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection
Vanessa Kappel da Silva et al.
MOLECULAR NEUROBIOLOGY (2014)
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism
T. D. M. Hill et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19
Rongrong Jiang et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
Brenda E. Porter et al.
EPILEPSY & BEHAVIOR (2013)
Marijuana, endocannabinoids, and epilepsy: Potential and challenges for improved therapeutic intervention
Mackenzie E. Hofmann et al.
EXPERIMENTAL NEUROLOGY (2013)
Experimental Models of Status Epilepticus and Neuronal Injury for Evaluation of Therapeutic Interventions
Doodipala Samba Reddy et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect
Marta Solinas et al.
PLOS ONE (2013)
Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses
Sergiy Sylantyev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cannabidivarin is anticonvulsant in mouse and rat
A. J. Hill et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Successful use of fenfluramine as an add-on treatment for Dravet syndrome
Berten Ceulemans et al.
EPILEPSIA (2012)
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors
Alline Cristina Campos et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2012)
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Alline Cristina Campos et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2012)
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour
Serena Deiana et al.
PSYCHOPHARMACOLOGY (2012)
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
Nicholas A. Jones et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2012)
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report
Jose Alexandre S. Crippa et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Cannabidiol Reduces Ab- Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
Giuseppe Esposito et al.
PLOS ONE (2011)
Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress
Erica M. Granjeiro et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2011)
Likert scales, levels of measurement and the laws of statistics
Geoff Norman
ADVANCES IN HEALTH SCIENCES EDUCATION (2010)
Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors
T. V. Zanelati et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis
Susanne A. Wolf et al.
CELL COMMUNICATION AND SIGNALING (2010)
Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action
P. J. Lucassen et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2010)
Increased Risk of Death Among Children With Lennox-Gastaut Syndrome and Infantile Spasms
Andrew R. Autry et al.
JOURNAL OF CHILD NEUROLOGY (2010)
Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
Nicholas A. Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors
A. Castillo et al.
NEUROBIOLOGY OF DISEASE (2010)
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2
R. G. Pertwee et al.
PHARMACOLOGICAL REVIEWS (2010)
Endogenous cannabinoid signaling is essential for stress adaptation
Matthew N. Hill et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives
Doodipala Samba Reddy
Expert Review of Clinical Pharmacology (2010)
The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling
J. M. Bessa et al.
MOLECULAR PSYCHIATRY (2009)
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin
R. G. Pertwee
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Inhibition of recombinant human T-type calcium channels by Δ9-Tetrahydrocannabinol and cannabidiol
Hamish Redmond Ross et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption
Mohanraj Rajesh et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2007)
Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy
Laxmikant S. Deshpande et al.
NEUROSCIENCE LETTERS (2007)
Human cannabinoid pharmacokinetics
Marilyn A. Huestis
CHEMISTRY & BIODIVERSITY (2007)
The tuberous sclerosis complex
Peter B. Crino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats
Leonardo B. M. Resstel et al.
BEHAVIOURAL BRAIN RESEARCH (2006)
Clinical spectrum of mutations in SCN1A gene: Severe myoclonic epilepsy in infancy and related epilepsies
Tateki Fujiwara
EPILEPSY RESEARCH (2006)
The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum
Y Kawamura et al.
JOURNAL OF NEUROSCIENCE (2006)
Status epilepticus severity influences the long-term outcome of neurogenesis in the adult dentate gyrus
P Mohapel et al.
NEUROBIOLOGY OF DISEASE (2004)
Chronic temporal lobe epilepsy is dentate neurogenesis in the adult associated with severely declined hippocampus
B Hattiangady et al.
NEUROBIOLOGY OF DISEASE (2004)
The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy
MJ Wallace et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity
MJ Wallace et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes
AN Gifford et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
A risk-benefit assessment of therapies for Lennox-Gastaut syndrome
D Schmidt et al.
DRUG SAFETY (2000)
Early identification of refractory epilepsy.
P Kwan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Gabaergic interneurons are the targets of cannabinoid actions in the human hippocampus
I Katona et al.
NEUROSCIENCE (2000)
Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons
AJ Irving et al.
NEUROSCIENCE (2000)
分享论文
